

BMJ Open Corticosteroids in sepsis: an updated systematic review and meta-analysis (protocol)

Bram Rochweg,^{1,2} Simon Oczkowski,¹ Reed Alexander Siemieniuk,² Kusum Menon,³ Wojciech Szczeklik,^{1,4} Shane English,^{5,6} Thomas Agoritsas,^{2,7} Emilie Belley-Cote,^{1,2} Frédérick D'Aragnon,⁸ Waleed Alhazzani,^{1,2} Erick Duan,^{1,2} Kira Gossack-Keenan,¹ Jon Sevransky,⁹ Per Vandvik,^{1,10} Bala Venkatesh,¹¹ Gordon Guyatt,¹² Djillali Annane^{1,13}

To cite: Rochweg B, Oczkowski S, Siemieniuk RA, *et al*. Corticosteroids in sepsis: an updated systematic review and meta-analysis (protocol). *BMJ Open* 2017;**7**:e016847. doi:10.1136/bmjopen-2017-016847

► Prepublication history and additional material are available. To view these files please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-016847>).

Received 15 March 2017
Revised 21 May 2017
Accepted 24 May 2017

ABSTRACT

Introduction Sepsis is associated with a dysregulated host response to infection and impaired endogenous corticosteroid metabolism. As such, therapeutic use of exogenous corticosteroids is a promising adjunctive intervention. Despite a large number of trials examining this research question, uncertainty persists regarding the effect of corticosteroids on survival in sepsis. Several large randomised controlled trials have been published recently prompting a re-evaluation of the available literature.

Methods and analysis A rigorous and reproducible search and screening process from a Cochrane review on the same topic was comprehensive to October 2014. We will search MEDLINE, EMBASE, LILACS, the Cochrane trial registry and clinicaltrials.gov for eligible randomised controlled trials investigating the use of corticosteroids in patients with sepsis from September 2014. Outcomes have been chosen by a semi-independent guideline panel, created in the context of a parallel *BMJ* Rapid Recommendation on the topic. This panel includes clinicians, content experts, methodologists and patient representatives, who will help identify patient-important outcomes that are critical for deciding whether to use or not use corticosteroids in sepsis. Two reviewers will independently screen and identify eligible studies; a third reviewer will resolve any disagreements. We will use RevMan to pool effect estimates from included studies for each outcome using a random-effect model. We will present the results as relative risk with 95% CI for dichotomous outcomes and as mean difference or standardised mean difference for continuous outcomes with 95% CI. We will assess the certainty of evidence at the outcome level using the Grading of Recommendations, Assessment, Development and Evaluation approach. We will conduct a priori subgroup analyses, which have been chosen by the parallel *BMJ* Rapid Recommendation panel.

Ethics and dissemination The aim of this systematic review is to summarise the updated evidence on the efficacy and safety of corticosteroids in patients with sepsis.

Trial registration number CRD42017058537.

BACKGROUND

Description of the condition

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host

Strengths and limitations of this study

- Systematic and comprehensive search.
- Multidisciplinary team including oversight and input from semi-independent *BMJ* Rapid Recommendation panel which includes patient and carer representatives.
- The results of this review will directly inform *BMJ* Rapid Recommendation clinical practice guideline recommendation.
- Application of Grading of Recommendations, Assessment, Development and Evaluation methodology to assess certainty in summarised estimates of effect.
- Anticipated clinical heterogeneity in individual study populations and intervention (including dosing, timing and formulation of corticosteroids).

response to infection.¹ The primary immune mechanisms include hyperstimulation of the inflammatory cascade and upregulation of related cytokines (including tumour necrosis factor- α , interleukin (IL)-1, IL-6). Haemodynamic instability secondary to vasodilation and dysregulation of coagulation and fibrinolysis are key contributors to tissue hypoperfusion and organ injury.² Septic shock is defined by the need for vasopressors to maintain a mean arterial pressure over ≥ 65 mm Hg and a serum lactate >2 mmol/L in the absence of hypovolaemia.

The incidence of sepsis varies from 900 000 to 3 million cases in the USA per year depending on the epidemiological methodology employed.^{3 4} In-hospital mortality of sepsis ranges from 14.7% to 30% in children and adults.^{3 5} Although hospital mortality rates from sepsis may have declined over the last 20 years, the incidence of sepsis seems to be increasing.⁶



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Bram Rochweg; rochweg@mcmaster.ca

Description of intervention

The sympathetic nervous system is activated by external stressors, such as sepsis, leading to the release of endogenous catecholamines and cortisol from the adrenal glands. Cortisol is the major endogenous glucocorticoid in the body and downregulates production of inflammatory cytokines through inhibition of nuclear factor- κ B.⁷ Cortisol also has other physiological effects in the body including increasing glucose levels (through enhanced hepatic gluconeogenesis and decreased peripheral glucose uptake) and increasing blood pressure (via increasing sensitivity to catecholamines).

Corticosteroids are synthetic cortisol compounds, which exert similar effects to their endogenous counterparts. In addition to glucocorticoid activity, many synthetic corticosteroids also have mineralocorticoid components that serve as substrate precursors for catecholamine synthesis.⁸ Some of the corticosteroids that have been investigated in the setting of sepsis include hydrocortisone,^{9–16} methylprednisolone^{17–20} and prednisone.^{21–22} Dosing regimens vary considerably with some studies giving large doses over 2–3 days and then stopping and others giving lower doses over 1–2 weeks with a gradual taper.

How the intervention might work

Cortisol deficiency in sepsis is likely multifactorial, usually reversible and results in an inadequate amount of cortisol at the tissue level.²³ Likewise, tissue resistance to corticosteroids is multifactorial and may involve alteration in the number or function of glucocorticoid receptors, cortisol metabolism or access to tissues. The result of removing this 'check' on the host immune response is unregulated activation of the inflammatory cascade leading to end-organ dysfunction. Also, the relative deficiency of mineralocorticoids may further contribute to systemic hypoperfusion, a subsequent decrease in oxygenated blood delivery to the periphery and further end-organ damage.

Exogenous supplementation with agents that have both glucocorticoid and mineralocorticoid activity is therefore a promising therapeutic option in patients with sepsis.

Why it is important to do this review

Despite strong physiological rationale for administration of corticosteroids in sepsis, uncertainty regarding the overall clinical effectiveness and the challenge of identifying patients who may benefit from their use has ultimately led to a high degree of practice variation.^{24–25} In the 55 years since the first randomised controlled trial (RCT) of corticosteroids in sepsis, their utility remains debated in the management of critically ill patients. The most recent systematic review suggested that steroids may reduce mortality in sepsis, although conclusions were based on low certainty in the evidence and were limited by imprecision, inconsistency and the potential for publication bias.²⁶ Results from this review suggested that patients with septic shock and those treated with a low dose and long course of corticosteroids had the highest likelihood of benefit.

Since the most recently published review, an additional large RCT was published²⁷ and another is planned for publication shortly.²⁸ Our updated systematic review and meta-analysis will include these two new trials, and any others identified in the updated search, in order to improve precision of the pooled point estimates of the treatment effect of corticosteroids in patients with sepsis. The new trials will provide data for at least 1600 additional patients from what we expect are trials at low risk of bias. This will substantially improve the power to detect clinically important effects; the previous review included 4200 patients from trials with various degrees of credibility.

This systematic review is part of the *BMJ* Rapid Recommendation project, a collaborative effort from the MAGIC research and innovation programme (www.magicproject.org) and *The BMJ*.²⁹ The aim of the project is to respond to new potentially practice-changing evidence and provide a trustworthy practice guideline in a timely manner. The anticipated publication of the APROCCHSS trial,³⁰ a multicentre trial that randomised 1241 patients with septic shock to receive hydrocortisone and fludrocortisone or placebo, is the trigger for this updated review. This systematic review will inform a parallel clinical practice guideline which will be published in a multilayered electronic format on *The BMJ* and MAGICapp.

Objectives

We plan to conduct a systematic review and meta-analysis of all published RCTs that have investigated the use of corticosteroids in critically ill patients with sepsis.

METHODS

Studies

We plan to include all RCTs reporting the use of corticosteroids in critically ill patients with sepsis. We will exclude case reports, case series and observational studies. We will not impose any methodological quality or language restrictions to the studies included and will appraise their risk of bias (see corresponding section below).

Participants

The population of interest includes all adult and children (excluding premature infants due to higher rates of adrenal insufficiency in this population³¹) who were diagnosed with sepsis, severe sepsis or septic shock according to appropriate criteria.^{1–32–33} We will include data from trials enrolling patients with acute respiratory distress syndrome if patients with sepsis are reported separately.

Interventions and comparators

The intervention of interest is the administration of systemic corticosteroids, including but not limited to cortisone, hydrocortisone, methylprednisolone, betamethasone, fludrocortisone and dexamethasone. We will only include RCTs with a placebo or no corticosteroid comparator group.

For the purposes of this review, high-dose corticosteroids will be considered any dose >400mg/day of

hydrocortisone or equivalent. Similarly, long duration of corticosteroid treatment will be considered ≥ 3 days. These operational definitions are rationalised based on a change in philosophy regarding the role of corticosteroids in sepsis that occurred in the late 1990s. Older studies administered very-high-dose and short duration corticosteroids attempting to maximise their anti-inflammatory effect, whereas newer studies used lower-dose and longer duration corticosteroids with the intent of compensating for a dysfunctional hypothalamic-pituitary axis response to stress.

Outcome measures

Patient-important outcomes have been chosen by a semi-independent parallel *BMJ* Rapid Recommendation guideline panel and include the outcomes that are critical for choosing whether to use corticosteroids in sepsis.³⁴

The outcomes are

- ▶ short-term mortality;
 - ▶ 90-day mortality;
 - ▶ 28-day, 30-day, hospital, intensive care unit (ICU) mortality (whichever is available);
- ▶ long-term mortality (closest to 1 year);
- ▶ number of participants with shock reversal at day 7 (stable haemodynamic status over 24 hours after withdrawal of vasopressors);
- ▶ organ dysfunction at day 7 (using total SOFA score);
- ▶ ICU length of stay;
- ▶ hospital length of stay;
- ▶ adverse events associated with corticosteroids including ICU-acquired neuromuscular weakness, gastrointestinal bleeding, neuropsychiatric effects, hyponatremia, superinfection, vascular events (stroke, myocardial infarction) and clinically significant hyperglycaemia;
- ▶ quality of life (using validated indices such as SF-36) at 1 year.

Search methods for identification of studies

A search and screening process from a Cochrane review on the same topic was credible and comprehensive to October 2014.³⁵ Using the same search strategy, we will search MEDLINE, EMBASE, LILACS and the Cochrane trial registry for RCTs investigating the use of corticosteroids in patients with sepsis from a database entry date of September 2014. We will not use any language restrictions. See online supplementary appendix 1 for MEDLINE search strategy. Keyword search terms include corticosteroids, sepsis and septic shock.

Searching other resources

We will search the references of review articles and systematic reviews on the same topic for eligible articles. In addition, we will search for unpublished or ongoing trials on the WHO international clinical trials registry, current controlled trials metaregister of controlled trials and clinicaltrials.gov database. Two reviewers will search conference proceedings from the Society of Critical Care

Medicine, American Thoracic Society and the European Society of Intensive Care Medicine (2014 and onwards).

Data collection and analysis

On implementation of our search strategy, reviewers working in pairs will independently screen all citations and references using specific eligibility criteria. If disagreements between the two primary reviewers cannot be resolved by discussion and consensus, a third reviewer will make the final determination of trial eligibility. We will attempt to contact study authors to obtain missing information necessary to judge trial eligibility.

Data extraction and management

Data extraction will be done independently and in duplicate using predesigned data abstraction forms. Abstracted data will include study title, first author, relevant demographic data, details of the intervention and control, primary and secondary outcome data, and information on methodological quality for each study. A third reviewer will resolve inconsistent data extraction between the two reviewers. We will perform data collection on studies included in the previous review³⁵ only for outcomes or subgroups that were not previously reported.

Assessment of risk of bias in included studies

Two reviewers will independently assess the risk of bias for each included study using the modified version of the Cochrane Collaboration tool.³⁶ Risk of bias assessment will be performed for individual studies separately for each outcome. A third reviewer will resolve disagreements.

The included RCTs will be assessed for sequence generation, allocation sequence concealment, blinding, selective outcome reporting and missing participant data. Sequence generation will be considered adequate if the study explicitly described an appropriate randomisation procedure to generate an unpredictable sequence of allocation, including computerised randomisation, use of random number tables and coin-tossing. Concealment of allocation will be considered adequate if specific methods to protect allocation were documented and implemented. Performance bias will be considered low if a study reported participant, caregiver and/or researcher blinding. Blinding of outcome assessment will be considered adequate if outcome assessors and adjudicators were blinded. Within-study selective reporting of outcomes will be examined by reviewing the a priori study protocol, if available. If the study protocol is not available, we will compare the outcomes listed in the methods section with the reported outcomes in the results section.

A description for each domain assessed will be included along with comments if necessary and a final judgement for each outcome within each study and categorised as (1) low risk of bias, where bias is not present or, if present, unlikely to affect outcomes; (2) probably low risk of bias; (3) probably high risk of bias; or (4) high risk of bias, where outcomes are likely to be significantly affected

by bias. We will consider the highest risk of bias for any criteria as the overall risk of bias for the study.

Measures of treatment effect

We will use RevMan V.5.3 software to conduct meta-analyses. We will use the method of DerSimonian and Laird for random-effects model to pool effect sizes for each outcome. Study weights will be generated using the inverse variance method. We will present the results as relative risk with 95% CI for dichotomous outcomes and as mean difference (MD) or standardised MD for continuous outcomes with 95% CI. We plan to perform random-effect analysis for all outcomes of interest.

We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to quantify the absolute magnitude of effect. We will use representative and trustworthy observational studies to measure baseline risk and apply the relative effect measured from the meta-analysis to obtain absolute differences (risk difference or MD) with a 95% CI. The risk difference with 95% CI will be derived from pooled risk ratios and its 95% CI using assumed control risk for each outcome.³⁷

Dealing with missing data

Where possible, if missing data are encountered we will attempt to contact the individual study authors for additional information. If this is not possible, we will analyse the available data and report on the potential impact of missing data on the results in the discussion section. We will perform a complete case analysis as the primary analysis for all outcomes and perform sensitivity analyses with increasingly extreme assumptions for missing participant data.³⁸

Assessment of reporting biases

We will look for potential publication bias using a funnel plot if >10 trials are included. For continuous outcomes, the Egger test³⁹ will be used to detect funnel plot asymmetry. For dichotomous outcomes, the arcsine test will be used. All analyses will be performed using RevMan or R.

Subgroup analysis and investigation of heterogeneity

We will assess for heterogeneity between studies using the χ^2 test for homogeneity, where $p < 0.10$ indicates substantial heterogeneity, and the I^2 statistic, in addition to visual inspection of the forest plots for magnitude of differences. If subgroup effects are credible, we will present the outcomes separately for each subgroup.⁴⁰ If serious heterogeneity remains, we will rate down our certainty in the effect estimate.⁴¹

We will conduct a priori subgroup analyses, which were chosen by the parallel *BMJ*/Rapid Recommendation panel (hypothesised direction of effect in parentheses):

- ▶ risk of bias (corticosteroids more effective in trials with high risk of bias);
- ▶ treatment dose (corticosteroids more effective in trials with lower doses);

- ▶ treatment duration (corticosteroids more effective in trials with longer duration);
- ▶ treatment molecule (corticosteroids more effective in trials with drugs having more mineralocorticoid activity);
- ▶ sepsis population subtype (sepsis, septic shock, pneumosepsis) (corticosteroids most effective in patients with pneumonia and those with septic shock, and least effective in patients with non-pneumonia sepsis without shock);
- ▶ age of patients (corticosteroids more effective in studies enrolling children (<18 years) than adults);
- ▶ presence of critical illness-related corticosteroid insufficiency (CIRCI) (corticosteroids more effective in trials identifying and enrolling patients with CIRCI).

For subgroup analyses, we will perform meta-regression if a sufficient number of studies are found (generally >10). If not, we will use the χ^2 test for each subgroup hypothesis, and then meta-regression if more than one is found to be statistically significant (using a p value threshold of <0.10).

Sensitivity analysis

Sensitivity analysis will be performed excluding studies only reported as abstracts.

Assessing the certainty of evidence

The GRADE approach will be used to assess the certainty of evidence for each outcome.⁴² The GRADE system classifies the certainty of the aggregate body of evidence as high, moderate, low or very low. The evidence will be evaluated using the following criteria: (1) study design and rigour of its execution (ie, individual study risk of bias), (2) the extent to which the evidence could be applied to patients of interest (ie, directness), (3) the consistency of results, (4) the analysis of the results (ie, precision) and (5) whether there is a likelihood of publication bias.

For each outcome, a final overall certainty of evidence will be summarised for the intervention taking into consideration both desirable and undesirable outcomes. An evidence profile will be included in the results showing the GRADE assessments and pooled analysis per outcome.

GUIDELINE PANEL AND PATIENT INVOLVEMENT

According to the *BMJ* Rapid Recommendations process,³⁴ the guideline panel has already provided critical oversight and identified populations, subgroups and outcomes of interest for this review. The panel includes content experts, methodologists and patients or carers with personal experience with sepsis. The panel is considered semi-independent of the systematic review team as four individuals are members of both. All patients receive personal training and support to optimise contributions throughout the guideline development process. The patient panel members will be invited to lead the interpretation of the results based on what they expect the

typical patient values and preferences to be, as well as the variation between patients.

DISCUSSION

Despite a large body of evidence, the role of corticosteroids in sepsis remains controversial. Given the forthcoming availability of new data addressing this research question, an updated systematic review and meta-analysis is needed to generate the best summary of evidence in order to help guideline developers and to assist bedside clinicians. This systematic review will summarise the RCT data on the efficacy and safety of corticosteroid use in critically ill patients with sepsis. Also, as future trial results become available (eg, NCT01448109) we will be able to rapidly incorporate the results into this evidence summary.

Strengths of this protocol include a comprehensive search strategy of published and unpublished literature, a priori subgroup analysis plan and inclusion of GRADE methodology to characterise the certainty in evidence and confidence in the estimates of effect. Results of this review will be accompanied by a *BMJ* Rapid Recommendation^{34 43–45} for front-line clinicians. Limitations relate to the anticipated clinical heterogeneity of patients, corticosteroid regimens and outcome assessments from included studies.

Author affiliations

¹Department of Medicine, McMaster University, Hamilton, Ontario, Canada

²Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada

³Department of Pediatrics, University of Ottawa, Ottawa, Ontario, Canada

⁴Department of Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland

⁵Department of Medicine (Critical Care), University of Ottawa, Ottawa, Ontario, Canada

⁶Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

⁷Division of General Internal Medicine & Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland

⁸Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke et Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada

⁹Division of Pulmonary, Allergy and Critical Care, Department of Medicine, Emory University, Atlanta, Georgia, USA

¹⁰Department of Medicine, Inlandet Hospital Trust-Division Gjøvik, Norway

¹¹Department of Intensive Care, Wesley Hospital and Princess Alexandra Hospital, University of Queensland, St Lucia, Australia

¹²University of Sydney, Sydney, Australia

¹³Hôpital Raymond Poincaré, Laboratory of Infection and Inflammation, University of Versailles, Garches, France

Acknowledgements We would like to express our gratitude to Jean Maragno and Lois Cottrel for their guidance in designing and carrying out our search strategy. Drs. Bram Rochweg and Simon Oczkowski are supported by McMaster University Department of Medicine early career research awards.

Contributors BR, RS, TA, PV and GG conceived the idea for this systematic review. All authors developed the methodology for the systematic review. The manuscript was drafted by BR and revised by all authors. BR and SO will screen potential studies, perform duplicate independent data abstraction, risk of bias assessment and GRADE assessment with help from RS, TA, WS, WA, ED, FD, EBC and KGK. BR will conduct the data synthesis. BR is the guarantor of the review.

Competing interests BR and SO are supported by McMaster University Department of Medicine early career research awards.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Singer M, Deutschman CS, Seymour CW, *et al.* The Third International Consensus Definitions for Sepsis and Septic shock (Sepsis-3). *JAMA* 2016;315:801–10.
2. Vincent JL, De Backer D. Circulatory shock. *N Engl J Med* 2014;370:583.
3. Gaieski DF, Edwards JM, Kallan MJ, *et al.* Benchmarking the incidence and mortality of severe Sepsis in the United States. *Crit Care Med* 2013;41:1167–74.
4. Rhee C, Murphy MV, Li L, *et al.* Improving documentation and coding for acute organ dysfunction biases estimates of changing Sepsis severity and burden: a retrospective study. *Crit Care* 2015;19:338.
5. Weiss SL, Fitzgerald JC, Pappachan J, *et al.* Global epidemiology of pediatric severe Sepsis: the Sepsis prevalence, outcomes, and therapies study. *Am J Respir Crit Care Med* 2015;191:1147–57.
6. Stevenson EK, Rubenstein AR, Radin GT, *et al.* Two decades of mortality trends among patients with severe Sepsis: a comparative meta-analysis*. *Crit Care Med* 2014;42:625–31.
7. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med* 1997;336:1066–71.
8. Annane D, Maxime V, Ibrahim F, *et al.* Diagnosis of adrenal insufficiency in severe Sepsis and septic shock. *Am J Respir Crit Care Med* 2006;174:1319–26.
9. Arabi YM, Aljumah A, Dabbagh O, *et al.* Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. *CMAJ* 2010;182:1971–7.
10. Bollaert PE, Charpentier C, Levy B, *et al.* Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998;26:645–50.
11. Briegel J, Forst H, Haller M, *et al.* Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999;27:723–32.
12. Confalonieri M, Urbino R, Potena A, *et al.* Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. *Am J Respir Crit Care Med* 2005;171:242–8.
13. El-Nawawy A, Khater D, Omar H, *et al.* Evaluation of Early Corticosteroid Therapy in Management of Pediatric Septic Shock in Pediatric Intensive Care Patients: A Randomized Clinical Study. *Pediatr Infect Dis J* 2017;36:155–9.
14. Gordon AC, Mason AJ, Perkins GD, *et al.* The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. *Crit Care Med* 2014;42:1325–33.
15. Oppert M, Schindler R, Husung C, *et al.* Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. *Crit Care Med* 2005;33:2457–64.
16. Sprung CL, Annane D, Keh D, *et al.* Hydrocortisone therapy for patients with septic shock. *N Engl J Med* 2008;358:111–24.
17. Bone RC, Fisher CJ, Clemmer TP, *et al.* A controlled clinical trial of high-dose methylprednisolone in the treatment of severe Sepsis and septic shock. *N Engl J Med* 1987;317:653–8.
18. Luce JM, Montgomery AB, Marks JD, *et al.* Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. *Am Rev Respir Dis* 1988;138:62–8.
19. Meduri GU, Golden E, Freire AX, *et al.* Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. *Chest* 2007;131:954–63.
20. Sprung CL, Caralis PV, Marcial EH, *et al.* The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. *N Engl J Med* 1984;311:1137–43.
21. Snijders D, Daniels JM, de Graaff CS, *et al.* Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. *Am J Respir Crit Care Med* 2010;181:975–82.

22. Yildiz O, Doganay M, Aygen B, *et al.* Physiological-dose steroid therapy in Sepsis [ISRCTN36253388]. *Crit Care* 2002;6:251–9.
23. Marik PE, Pastores SM, Annane D, *et al.* Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of critical Care Medicine. *Crit Care Med* 2008;36:1937–49.
24. Bruno JJ, Dee BM, Anderegg BA, *et al.* US practitioner opinions and prescribing practices regarding corticosteroid therapy for severe Sepsis and septic shock. *J Crit Care* 2012;27:351–61.
25. Menon K, McNally JD, Choong K, *et al.* A survey of stated physician practices and beliefs on the use of steroids in pediatric fluid and/or vasoactive infusion-dependent shock. *Pediatr Crit Care Med* 2013;14:462–6.
26. Annane D, Bellissant E, Bollaert PE, *et al.* Corticosteroids for treating sepsis. *Cochrane Database Syst Rev* 2015;12:CD002243.
27. Keh D, Trips E, Marx G, *et al.* Effect of hydrocortisone on development of shock among patients with severe Sepsis: the HYPRESS Randomized clinical trial. *JAMA* 2016;316:1775–85.
28. Annane D, Buisson CB, Cariou A, *et al.* Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial. *Ann Intensive Care* 2016;6:43.
29. Siemieniuk RA, Agoritsas T, Macdonald H, *et al.* Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191.
30. Annane D, Buisson CB, Cariou A, *et al.* Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial. *Ann Intensive Care* 2016;6:43.
31. Korte C, Styne D, Merritt TA, *et al.* Adrenocortical function in the very low birth weight infant: improved testing sensitivity and association with neonatal outcome. *J Pediatr* 1996;128:257–63.
32. Levy MM, Fink MP, Marshall JC, *et al.* 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. *Crit Care Med* 2003;31:1250–6.
33. Bone RC, Balk RA, Cerra FB, *et al.* Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992;101:1644–55.
34. Siemieniuk RA, Agoritsas T, Macdonald H, *et al.* Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191.
35. Annane D, Bellissant E, Bollaert PE, *et al.* Corticosteroids for treating sepsis. *Cochrane Database Syst Rev* 2015:CD002243.
36. Bond CM, Djogovic D, Villa-Roel C, *et al.* Pilot study comparing Sepsis management with and without electronic clinical practice guidelines in an academic emergency department. *J Emerg Med* 2013;44:698–708.
37. Higgins JP, Green S. *Cochrane handbook for systematic reviews of interventions*. Wiley Online Library, 2008.
38. Akl EA, Johnston BC, Alonso-Coello P, *et al.* Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. *PLoS One* 2013;8:e57132.
39. Higgins JP, Altman DG, Gotzsche PC, *et al.* The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
40. Sun X, Briel M, Busse JW, *et al.* Credibility of claims of subgroup effects in randomised controlled trials: systematic review. *BMJ* 2012;344:e1553.
41. Guyatt GH, Oxman AD, Kunz R, *et al.* GRADE guidelines: 7. Rating the quality of evidence--inconsistency. *J Clin Epidemiol* 2011;64:1294–302.
42. Guyatt GH, Oxman AD, Vist GE, *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
43. Vandvik PO, Otto CM, Siemieniuk RA, *et al.* Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic Stenosis at low to intermediate surgical risk: a clinical practice guideline. *BMJ* 2016;354:i5085.
44. Poolman RW, Agoritsas T, Siemieniuk RA, *et al.* Low intensity pulsed ultrasound (LIPUS) for bone healing: a clinical practice guideline. *BMJ* 2017;356:j576.
45. Siemieniuk RAC, Harris IA, Agoritsas T, *et al.* Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline. *BMJ* 2017;357:j1982.